The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for Botulinum Neurotoxin Potency Testing

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Alternatives to laboratory animals : ATLA

• Publication date

  2010-08-01

• Fields of study

  Law, Medicine, Environmental Science

• Identifiers
  DOI 10.1177/026119291003800401PMID 20822324
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological characteristics and quality of botulinum toxin type A for injection

  2012cited by this paper
• Open letter to the German Chancellor Dr. Angela Merkel. Council Directive on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes.

  2010cited by this paper
• ynaptic currents and transmitter responses in human NT 2 neurons ifferentiated in aggregate culture

  2009cited by this paper
• Cellular phenotypes of human model neurons (NT2) after differentiation in aggregate culture

  2009cited by this paper
• The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use

  2009cited by this paper
• ICH Harmonised Tripartite Guideline

  2009cited by this paper
• Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice.

  2009cited by this paper
• The Intercostal NMJ Assay — A New Alternative to the Conventional LD50 Assay for the Determination of the Therapeutic Potency of Botulinum Toxin Preparations

  2008cited by this paper
• Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins.

  2008cited by this paper
• The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations.

  2008cited by this paper
• A neuronal cell‐based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies

  2007cited by this paper
• Human model neurons in studies of brain cell damage and neural repair.

  2007cited by this paper
• Detection of antibodies against botulinum toxins

  2004cited by this paper
• Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin.

  2003cited by this paper
• OECD GUIDELINE FOR THE TESTING OF CHEMICALS

  2002cited by this paper
• Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.

  2002cited by this paper
• A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.

  2001cited by this paper
• Neurotoxins affecting neuroexocytosis.

  2000cited by this paper
• Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Å resolution

  2000cited by this paper
• Validation of in vitro assays for botulinum toxin: a case study.

  1999cited by this paper
• Quality of biotechnological products : Stability testing of biotechnological/ biological products : International Conference on Harmonisation (ICH)

  1998cited by this paper
• Recombinant expression and purification of the botulinum neurotoxin type A translocation domain.

  1997cited by this paper
• Botulinum A toxins: units versus units

  1997cited by this paper
• Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro.

  1997cited by this paper
• Therapeutic botulinum type A toxin: factors affecting potency.

  1996cited by this paper
• Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin.

  1996cited by this paper
• Botulinum neurotoxins are zinc proteins.

  1992cited by this paper
• Molecular pharmacology of botulinum toxin and tetanus toxin.

  1986cited by this paper
• The Code of Federal Regulations

  1986cited by this paper
• Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis

  1986cited by this paper
• Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization

  1984cited by this paper
• The origin, structure, and pharmacological activity of botulinum toxin.

  1981cited by this paper
• Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction.

  1980cited by this paper

• The mouse diaphragm assay in botulinum toxin therapy.

  2026cites this paper
• Evaluation of a Cell-Based Potency Assay for Detection of the Potency of TrenibotulinumtoxinE® (TrenibotE)

  2025cites this paper
• A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A.

  2024cites this paper
• A Validation of the Equivalence of the Cell-Based Potency Assay Method with a Mouse LD50 Bioassay for the Potency Testing of OnabotulinumtoxinA

  2024cites this paper
• EGFP/RFP-based FRET sensors for botulinum neurotoxin A biological activity detection and methodological validation.

  2024cites this paper
• Replacement of the Mouse LD50 Assay for Determination of the Potency of AbobotulinumtoxinA with a Cell-Based Method in Both Powder and Liquid Formulations

  2023cites this paper
• Recent Developments in Botulinum Neurotoxins Detection

  2022cites this paper
• Critical analysis in the advancement of cell-based assays for botulinum neurotoxin

  2022cites this paper
• Botulinum toxin therapy: past, present and future developments

  2022cites this paper
• Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations

  2022cites this paper
• Neural correlates of enhanced response inhibition in the aftermath of stress

  2020cites this paper
• Transferability study of the BINACLE (binding and cleavage) assay for in vitro determination of botulinum neurotoxin activity.

  2020cites this paper
• Analysis of Motor Neurons Differentiated from Human Induced Pluripotent Stem Cells for the Use in Cell-Based Botulinum Neurotoxin Activity Assays

  2020cites this paper
• Critical Analysis of Neuronal Cell and the Mouse Bioassay for Detection of Botulinum Neurotoxins

  2019cites this paper
• Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays

  2019influential citation
• Botulinum toxin testing on animals is still a Europe-wide issue.

  2019influential citation
• In vitro quantification of botulinum neurotoxin type A1 using immobilized nerve cell-mimicking nanoreactors in a microfluidic platform.

  2019cites this paper
• Botulinum Neurotoxin Detection Methods for Public Health Response and Surveillance

  2018cites this paper
• Minimal Lethal Disturbance for Finite Dimensional Linear Systems

  2018cites this paper
• Botulinum neurotoxin formulations: overcoming the confusion

  2018cites this paper
• A Cell Line for Detection of Botulinum Neurotoxin Type B

  2017cites this paper
• SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E

  2017cites this paper
• Immuno-detection of cleaved SNAP-25 from differentiated mouse embryonic stem cells provides a sensitive assay for determination of botulinum A toxin and antitoxin potency.

  2017cites this paper
• Engineering Botulinum Neurotoxin C1 as a Molecular Vehicle for Intra-Neuronal Drug Delivery

  2017cites this paper
• Assessment of ELISA as endpoint in neuronal cell-based assay for BoNT detection using hiPSC derived neurons.

  2017cites this paper
• Embryonic Stem Cell-Derived Neurons Grown on Multi-Electrode Arrays as a Novel In vitro Bioassay for the Detection of Clostridium botulinum Neurotoxins

  2017cites this paper
• Medium Optimization for Synaptobrevin Production Using Statistical Methods

  2017cites this paper
• Rapid Tests for Detection of Main Clostridial Toxins

  2017cites this paper
• Botulinum Toxin: From Molecule to Medicine

  2017cites this paper
• In vitro potency determination of botulinum neurotoxin B based on its receptor-binding and proteolytic characteristics.

  2016cites this paper
• Nerve cell-mimicking liposomes as biosensor for botulinum neurotoxin complete physiological activity.

  2016cites this paper
• Botulinum toxin B increases intrinsic muscle activity in organotypic spinal cord-skeletal muscle co-cultures.

  2016cites this paper
• The role of neurotoxins in the periorbital and midfacial areas.

  2015cites this paper
• Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN)

  2015cites this paper
• Stress response of Group I and II Clostridium botulinum

  2015cites this paper
• Improved bioassays using a local effect, such as muscle paralysis, as an endpoint.

  2015cites this paper
• A chip-based assay for botulinum neurotoxin A activity in pharmaceutical preparations

  2015cites this paper
• Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples

  2015cites this paper
• Generation and Characterization of Six Recombinant Botulinum Neurotoxins as Reference Material to Serve in an International Proficiency Test

  2015cites this paper
• Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products

  2015cites this paper
• Spinal cord--skeletal muscle cocultures detect muscle-relaxant action of botulinum neurotoxin A.

  2014cites this paper
• Development of a prediction method for skin sensitization using novel cysteine and lysine derivatives.

  2014cites this paper
• On the role of co-inhibitory molecules in dendritic cell: T helper cell coculture assays aimed to detect chemical-induced contact allergy.

  2014cites this paper
• Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery

  2014cites this paper
• Establishment of alternative potency test for botulinum toxin type A using compound muscle action potential (CMAP) in rats.

  2014cites this paper
• Progress in cell based assays for botulinum neurotoxin detection.

  2013cites this paper
• Abo‐, Inco‐, Ona‐, and Rima‐Botulinum Toxins in Clinical Therapy: A Primer

  2013cites this paper
• The Botulinum Toxin LD50 Potency Assay — Another Chapter, Another Mystery

  2012cites this paper
• Mouse compound muscle action potential assay: an alternative method to conduct the LD₅₀ botulinum toxin type A potency test.

  2012influential citation
• The Potency Testing of Botulinum Neurotoxin Products

  2012cites this paper
• Bioassays for evaluation of medical products derived from bacterial toxins.

  2012cites this paper
• Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay

  2012influential citation
• Neurotransmitter Vesicle Release from Human Model Neurons (NT2) is Sensitive to Botulinum Toxin A

  2012cites this paper
• Reply to comment on "The Botulinum Neurotoxin LD50 Test - Problems and Solutions"

  2011cites this paper
• Alternatives to animal testing: current status and future perspectives

  2011cites this paper
• Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010

  2011cites this paper
• Comment on "The Botulinum Neurotoxin LD50 Test - Problems and Solutions"

  2011cites this paper
• Author Index

  2010cites this paper